Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV).

[1]  M. Rennels,et al.  Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. , 2003, Pediatrics.

[2]  K. Eguchi,et al.  Short interfering RNA‐directed inhibition of hepatitis B virus replication , 2003, FEBS letters.

[3]  R. Sun,et al.  Inhibition of Gammaherpesvirus Replication by RNA Interference , 2003, Journal of Virology.

[4]  D. Weissman,et al.  Inhibition of HIV-1 Infection by Small Interfering RNA-Mediated RNA Interference1 , 2002, The Journal of Immunology.

[5]  J. Milner,et al.  Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference , 2002, Oncogene.

[6]  S. Leader,et al.  Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999 , 2002, The Pediatric infectious disease journal.

[7]  P. Collins,et al.  Respiratory Syncytial Virus Infection of Human Airway Epithelial Cells Is Polarized, Specific to Ciliated Cells, and without Obvious Cytopathology , 2002, Journal of Virology.

[8]  A. Levin,et al.  Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma. , 2002, Analytical biochemistry.

[9]  T. Tuschl,et al.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells , 2001, Nature.

[10]  J. Devincenzo,et al.  Therapy of respiratory syncytial virus infection. , 2000, The Pediatric infectious disease journal.

[11]  E. Walsh,et al.  Respiratory Syncytial Virus Infection in Adults , 2000, Clinical Microbiology Reviews.

[12]  R. Couch,et al.  Impact of respiratory virus infections on persons with chronic underlying conditions. , 2000, JAMA.

[13]  R. Lehmann,et al.  Targeted mRNA degradation by double-stranded RNA in vitro. , 1999, Genes & development.

[14]  A. Fire,et al.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans , 1998, Nature.

[15]  U. Schaad,et al.  Treatment of respiratory syncytial virus bronchiolitis: 1995 poll of members of the European Society for Paediatric Infectious Diseases. , 1997, The Pediatric infectious disease journal.

[16]  W. Gruber,et al.  Twenty years of outpatient respiratory syncytial virus infection: a framework for vaccine efficacy trials. , 1997, Pediatrics.

[17]  W. P. Glezen,et al.  Risk of primary infection and reinfection with respiratory syncytial virus. , 1986, American journal of diseases of children.

[18]  F. W. Denny,et al.  Epidemiology of acute lower respiratory disease in children. , 1973, The New England journal of medicine.

[19]  B. Graham,et al.  The histopathology of fatal untreated human respiratory syncytial virus infection , 2007, Modern Pathology.

[20]  R. Jacobs,et al.  Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. American Academy of Pediatrics Committee on Infectious Diseases. , 1996, Pediatrics.